About SHAPE Task Force | SHAPE Society

top of page

SHAPE Presentations

AHA SHAPE Symposium 2017 Dr. Naghavi Presentation

AHA SHAPE Symposium 2017 Dr. Kloner Presentation

AHA SHAPE Symposium 2017 Dr. Greenland Presentation

AHA SHAPE Symposium 2017 Dr. Yen Presentation

AHA SHAPE Symposium 2017 Dr. Slomka Presentation

yqfrfxb7qwo39m6toen0-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vu lplaque1 pasterkamp

mad1uuxsskkir8nfuqlw-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable plaque vulnerable patient

mfswhnjpr3ahzsvoax8m-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable plaque overview

5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable patient talk in poland

5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable patient slides without movies

5ditljhlts6wpijskvjo-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable patient slides with movies

bpjjjkqjygttwobapucq-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable patient mar 04

cpp5sfazstuhymrh0g42-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vulnerable (thrombogenic blood

bruhekbarg7gskc8arr5-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vuln shape aha 2005

ong6ubwbrjq0x2yzitcv-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vuln plaque poster burke

20rxh3kjsuyjnwejc65q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial_slide 25short-

d5hurgbs1w9jnhh9731a-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial_slide25

20rxh3kjsuyjnwejc65q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial_slide25short-

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch2002

mrsiewo9sjsvtf4brkz6-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp symposium31602

y9mlgowptgose5q1ufx2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vpschoenhagen

dzelv2glrcycowb4dqjh-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp meeting orlando2003_new template

y3vajtd9qw06r7t39u1q-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vpiii lobby-02

q3qv0cdbtgigvepxourd-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp

afxga6fzqd6f5jl0evnf-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp.org cimit harvard

6wxrmfw0sdkbvhryvvo8-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp texas by yuan

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial - v2 n3- 2002

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial - v2 n2- 2002

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial - v2 n6- 2002

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp watch editorial - v2 n4- 2002

mrsiewo9sjsvtf4brkz6-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp symposium 3 16-02

lk95kaeorr2v01lljt08-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp schoenhagen

jqnxzskctqdrdwauap6w-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp slides

urunil5aspu0uuoaxfme-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp presentation jar 3 29 03

rvfmfdsrg0vtc0pccezg-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp paper 7 pics (aeha logo)

q9edmehvrmmh1ghh4ypl-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp lightlab kolstad (industry)

yvuwde82qmwpgu7akdpn-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vp 2002 talk show copy galis

qqcykfpcq920odj2fflk-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Voorbeeld3 dhisto

ihvlgsq8rt2rnquoub7g-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Volcano avi

cnrd2utrdmfwgqdsu2to-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Visualization of atherosclerotic vulnerable plaque

pfa8ymtqr7yc7nyfqg2g-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vogel endothelial function cv es

14d2arihrra6tudqqugz-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Virmani

ojwxm3rj1qcdgbnhita2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vascular interventions

umclsflsth6se5pty4dx-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Virella

ojwxm3rj1qcdgbnhita2-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Vascular interventions atalar- johns hopkins

lxfj2r6sh2o1v6f8phup-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

V2n31

5lu1ficcsrs8mw7kg7ag-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Updated power point presentation of the vulnerable patient manuscript

abh3dfroqyidqm4j86hm-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Toyotaka

coaiqeqqqugfxiovwukg-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Transgenic cetp dahl salt sensitive (tg53) rat model

Towards immune modulation vp

Tlr4 circulation

Towards immune modulation vp 16 11 gkh

Tissue contrast

Thermographya novel approach for the identification of vp

Thermographya novel approach for the identification of vp

Thermographya novel approach for the identification of vp

Thermo elastography

Thermo elastography

Thermal hetrogeneity clinical syndrome 2

The fat fed apoe ko mouse- chris jackson- u of bristol

fducisgzqjc1kcjuwymv-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

The prevalence of inflammatory cells in non ruptured atherosclerotic plaques

The prev of inf cells in nonrupt a. plaque pasterkamp- part 2

The new design basket catheter system

The entire poster presentation of vp symposium acc 2003

n12nytesxkpwygo7eghl-signature-674a249b062fb8a4e201f5d0975d068538e3e23ab4b20ff18b08a1a266a

Tct recognition of vulnerable plaque guidelines

Tct fat poster-title

Tct mri 2001

Tct arrow pics, landscape

Taylor.aeha cac imt progression talk.1

Tawakol

Symposium jang

Stroes

Strains vp

suoyjwv0tmeuxuqecmc0-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Stephanes talk aeha

Stenosis vs risk

Stenosis severity and risk benefit

Stein cimt for shape 11-05

Stefanadis

Statins are associated

Statin periomort

Spio mri studies by dr naghavi-presented to ge-amersham

dkly80yztg2gq6tzeoqo-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Spio mri studies by dr naghavi

Spio mri studies by dr naghavi - presented to ge-amersham

Spio mri studies by dr naghavi - amersham oct 2003 - part 1

Spio cytokinejan28

Spio mri studies by dr naghavi - amersham oct 2003 - part2

Spio cytokinejan28-2

pl9gjgfbqzcq2dfcux6b-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Spio uptake by macrophages

yamqq8epqsgjju76bifn-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Spio photo

Spectroscopic fiber optic catheter tania - aha 2001

Spatial encoding part_2

Spect ct -dan berman

Slides 25 28

Slides 29 38

Slides naqvi

Slides 21 24

Slides 9 20

Slides 20 37 -vulnerable patient with movies

Slides 1 20 -vulnerable patient with movies

nqzawfeuqba7ozge9ymw-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Slides 1 8

Slides2938

Slides2528

Slides920

Slides2124

Slides18

Slagerperspective

Slide shows of uptake of spio by macrophages and monocytes10

Slager1

Silvio flu

Shuzou

Silvio sept 24

Shoenhagen

Shape a-thon clinton

Shape symposium slide presentation

Shape aha 2005

Seferovic

Shah vaccine

Schwartz debate aha 2002

Scd

Saloner presentation

Rumberger vp discussion 11 03

Rumberger 2nd vp symposium 3 6 04

Rumberger

Rumberg 4

Rumberg3

Revisiting the basics culprit vs non culprit

Revisiting the basics culprit vs non culprit

qfltloektdqhtrqoatix-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Rumberg1

Ricenano

Resp infection of apoe ko mice and plaque inflammation

Rumberg2

Research findings

Recent results and findings.

Progress with the a 3 fr nir fiber optic catheter

Pulse sequences gradient echo

Project introduction

Preset3

Presentation1

Ppt for adelson sketch

eh85igzxryys4hmm6hmt-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Positive remodeling slides for ralph

Positive remodeling for ralph

Polymophism in the promoter

Plaque petct

Pharmacologic treatment of vulnerable plaque

Plaque rupture definition

Plaque severity and coronary occlusion

Plaque inflammation july 2

Plaque inflammation in atherosclerotic rabbits

Plaque inflammation in atherosclerotic rabbits

Patrick updown

Plaque characterization with oct

agcvnmajrtaldu4hwgkv-signature-185c9c8f74195a69485b096cbf5bfb73f6b3ed8b7754452e736ee459818

Phil graham new

Peter libby, md

Periadventitial fat

Percutaneouse

Pbg vp mar02_final

Percutaneous coronary intervention by hossein

Percutaneouse coronary intervention

Pasterkamp1

Pasterkamp2

Pasterkamp

Pandemic of cvd atlanta

Out of hospital

Pancoronary therapy with ipdd

Out of hospital sudden cardiac death (scd) declining or escalating

Out of hospital sudden cardiac death(scd)

Out of hospital 2

Date: Mon Jan 8 4:33

Date: Mon Jan 8 4:32

Date: Mon Jan 8 4:31

Date: Mon Jan 8 4:30

Date: Mon Jan 8 4:27

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:32

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

Date: Mon Sep 19 19:16

bottom of page